Efficacy and Safety of Pemetrexed in Advanced Non-Small Cell Lung Carcinoma.
10.4046/trd.2009.67.2.121
- Author:
Gyu Jin LEE
1
;
Mann Hong JUNG
;
Tae Won JANG
;
Chul Ho OK
;
Hyun Joo JUNG
Author Information
1. Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea. jangtw@ns.kosinmed.or.kr
- Publication Type:Original Article
- Keywords:
Pemetrexed;
Non-small-cell lung carcinoma;
Drug therapy
- MeSH:
Carcinoma, Non-Small-Cell Lung;
Carcinoma, Squamous Cell;
Disease-Free Survival;
Glutamates;
Guanine;
Humans;
Lung;
Neutropenia;
Pemetrexed
- From:Tuberculosis and Respiratory Diseases
2009;67(2):121-126
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Pemetrexed has been prescribed newly as a second line chemotherapy in advanced non-small cell lung carcinoma (NSCLC). The aim of study was to determine the efficacy and toxicity of pemetrexed in advanced NSCLC. METHODS: Patients with histologically or cytologically confirmed NSCLC were evaluated from June 2006 to December 2008. The patients had relapsed or progressed after prior chemotherapy treatment. They were treated with intravenous pemetrexed 500 mg/m2 for 10 min on Day 1 of each 21-day cycle. RESULTS: A total of 89 patients were eligible for analysis. The response rate and disease control rate were 11% and 66%. Non-squamous cell carcinoma histology was significantly associated with a superior response rate (p=0.035) and disease control rate (p=0.009) than squamous cell carcinoma histology. The median survival time was 13 months and the median progression free survival time was 2.3 months. The median survival time of patients with ECOG PS 0~1 was 13.2 months, whereas median survival time was 11.6 months for patients with PS 2 (p=0.002). The median progression free survival time of patients with PS 0~1 were 3.8 months, but 2.1 months for patients with PS 2 (p=0.016). The median progression free survival time of smokers with non-squamous cell carcinoma was 3.4 months, which was significant (p=0.014). Grade 3~4 neutropenia were seen in 7.9% patients. CONCLUSION: Pemetrexed has efficacy in patients who had prior chemotherapy with advanced NSCLC and less hematologic toxicity.
